Jinshi Biological Technology (01548): CARVYKTI's net sales for the second quarter were approximately 657 million US dollars.

"According to the announcement released by the Zhitong Finance APP, Kingsley Biotechnology (01548) stated that based on the collaboration and licensing agreement signed with Legend and Janssen Biotech, Inc. (Johnson & Johnson) on December 21, 2017, CARVYKTI generated approximately $657 million in net sales in the quarter ending June 30, 2026."